Skip to main content

Table 4 Overview of PD-1/PD-L1 inhibitors with active clinical trials

From: Pembrolizumab

Compound Developing company Most advanced stage of development by cancer type
PD-1
Pembrolizumab (MK-3475, SCH 900475) Merck & Co. • Approved (various countries): advanced melanoma
• Phase III: head and neck cancer; melanoma; NSCLC; urothelial cancer; gastric/gastroesophageal junction adenocarcinoma
• Phase II: colorectal cancer; Merkel cell cancer; multiple myeloma; mycosis fungoides or Sezary syndrome; prostate cancer; soft tissue sarcoma; bone sarcoma; GBM; mesothelioma; Hodgkin lymphoma; non-Hodgkin lymphoma (DLBCL); breast cancer; small cell lung cancer; bladder cancer; thymic carcinoma; renal cell cancer; pancreatic cancer; chronic lymphocytic leukemia
• Phase I: advanced solid tumors; myelodysplastic syndrome; pontine gliomas; ovarian cancer
Nivolumab (BMS-936558, MDX1106, ONO-4538) Bristol-Myers Squibb/Ono Pharmaceutical • Approved (various countries): advanced melanoma; previously treated squamous cell NSCLC
• Phase III: gastric cancer; GBM; head and neck cancer; melanoma; NSCLC; renal cell carcinoma
• Phase II: acute myeloid leukemia; anal carcinoma; B-cell non-Hodgkin lymphoma; cervical cancer; follicular lymphoma; Hodgkin lymphoma; nasopharyngeal carcinoma; chronic lymphocytic leukemia; pancreatic adenocarcinoma; urothelial cancer; myelofibrosis
• Phase I: advanced solid tumors; breast cancer; chronic myeloid leukemia; colorectal cancer; DLBCL; Ewing sarcoma; hepatocellular carcinoma; multiple myeloma; osteosarcoma; ovarian cancer; rhabdomyosarcoma
Pidilizumab (CT-011) Curetech • Phase II: acute myelogenous leukemia; follicular lymphoma; multiple myeloma; pancreatic cancer; prostate cancer; renal cell carcinoma
• Phase I: glioma
AMP-224 Amplimmune/ GlaxoSmithKline • Phase I: colorectal cancer
AMP-514 (MEDI0680) Amplimmune • Phase I: advanced malignancies; B-cell lymphomas
REGN2810 Regeneron • Phase I: advanced malignancies
PD-L1
MPDL3280A Genentech/Roche • Phase III: NSCLC; urothelial cancer; renal cell carcinoma; breast cancer
• Phase II: colorectal cancer
• Phase I: advanced solid tumors; DLBCL; follicular lymphoma; melanoma
MEDI4736 Medimmune/AstraZeneca • Phase III: NSCLC; head and neck cancer
• Phase II: colorectal cancer; GBM
• Phase I: advanced solid tumors; B-cell lymphoma; cervical cancer; gastric/gastroesophageal junction cancer; melanoma; myelodysplastic syndrome; breast cancer; pancreatic cancer
BMS-936559 (MDX-1105) Bristol-Myers Squibb • Phase I: advanced solid tumors
MSB0010718C Merck Serono • Phase III: NSCLC
• Phase II: Merkel cell carcinoma
• Phase I: advanced solid tumors
  1. Information derived from ClinicalTrials.gov (access date: April 28, 2015)
  2. Abbreviations: DLBCL diffuse large B-cell lymphoma; GBM glioblastoma multiforme; NSCLC non-small cell lung cancer; PD-1 programmed death receptor 1; PD-L1 programmed death receptor ligand 1